• Better Screening for Prostate Cancer

    Impact Life Do What’s Right Innovate Together Build Community

  • The Problem

    Prostate Cancer is the second deadliest cancer for American men. More than 191,930 men will be diagnosed in 2020 and 33,330 will die from Prostate Cancer. Simultaneously, it is overdiagnosed and overtreated in men with indolent (less aggressive) prostate cancer. This leads to unnecessary treatments such as prostatectomy and radiation therapy.

    PSA: An Imperfect Screening Tool

    Prostate Specific Antigen or PSA is currently the standard test used for prostate cancer screening. However, it has several shortcomings, including:

    • PSA can be elevated for reasons other than Prostate Cancer.
    • PSA and its variants miss a large portion of aggressive Prostate Cancers.
    • PSA can’t distinguish between indolent and aggressive prostate cancers. Leading many patients to undergo unnecessary treatments.

    Screening is Declining

    Because the PSA test is no longer recommended, screening rates of men in the United States have declined. Lower screening reduces the overdiagnosis and overtreatment of Prostate Cancer as intended by the recommendation. However, by screening less men for Prostate Cancer, the aggressive cancers will also be missed. This will trigger more deaths that could have been avoided.

    Let's not abandon screening; let's build a better screening test.


    ● Impact Life ●

    We strive to make an impact on lives that can be saved, to have a positive impact on the lives of our patients, physicians, partners and employees.

    ● Do What's Right ●

    We will continue to always do whats right.

    ● Innovate Together ●
    We are building a better test to screen for and determine the aggressiveness of prostate cancer.


    ● Build Community ●

    Only with the community around us can we bring this screening test to the forefront and help more men get tested